Literature DB >> 32474680

Exendin-4 Attenuates Remodeling in the Remote Myocardium of Rats After an Acute Myocardial Infarction by Activating β-Arrestin-2, Protein Phosphatase 2A, and Glycogen Synthase Kinase-3 and Inhibiting β-Catenin.

Refaat A Eid1, Mohammad Adnan Khalil2, Mahmoud A Alkhateeb3, Samy M Eleawa4, Mohamed Samir Ahmed Zaki5,6, Attalla Farag El-Kott7,8, Mubarak Al-Shraim9, Fahmy El-Sayed9, Muhammad Alaa Eldeen10, Mashael Mohammed Bin-Meferij11, Khalid M E Awaji12, Abdullah S Shatoor13.   

Abstract

PURPOSE: This study tested if the protective anti-remodeling effect of GLP-1 agonist Exendin-4 after an acute myocardial infarction (MI) in rats involves inhibition of the Wnt1/β-catenin signaling pathway.
METHODS: Rats were divided into sham, sham + Exendin-4 (10 μg/day, i.p), MI, and MI + Exendin-4. MI was introduced to rats by permanent left anterior descending coronary artery (LAD) ligation.
RESULTS: On day 7 post-infraction, MI rats showed LV dysfunction with higher serum levels of cardiac markers. Their remote myocardia showed increased mRNA and protein levels of collagen I/III with higher levels of reactive oxygen species (ROS) and inflammatory cytokines, as well as protein levels of Wnt1, phospho-Akt, transforming growth factor (TGF-β1), Smad, phospho-Smad3, α-SMA, caspase-3, and Bax. They also showed higher protein levels of phospho-glycogen synthase kinase-3β (p-GSK3β), as well as total, phosphorylated, and nuclear β-catenin with a concomitant decrease in the levels of cyclic adenosine monophosphate (cAMP), mRNA of manganese superoxide dismutase (MnSOD), and protein levels of Bcl-2, β-arrestin-2, and protein phosphatase-2 (PP2A). Administration of Exendin-4 to MI rats reduced the infarct size and reversed the aforementioned signaling molecules without altering protein levels of TGF-1β and Wnt1 or Akt activation. Interestingly, Exendin-4 increased mRNA levels of MnSOD, protein levels of β-arrestin-2 and PP2A, and β-catenin phosphorylation but reduced the phosphorylation of GSK3β and Smad3, and total β-catenin levels in the LV of control rats.
CONCLUSION: Exendin-4 inhibits the remodeling in the remote myocardium of rats following acute MI by attenuating β-catenin activation and activating β-arrestin-2, PP2A, and GSK3β. Graphical Abstract A graphical abstract that illustrates the mechanisms by which Exendin-4 inhibits cardiac remodeling in remote myocardium of left ventricle MI-induced rats. Mechanisms are assumed to occur in the cardiomyocytes and/or other resident cells such as fibroblast. Β-catenin activation and nuclear translocation are associated with increased synthesis of inflammatory cytokines and transforming growth factor β-1 (TGF-β1). GSK3β is inhibited by phosphorylation at Ser9. Under normal conditions, β-catenin is degraded in the cytoplasm by the active GSK3β-dependent degradation complex (un-phosphorylated) which usually phosphorylates β-catenin at Ser33/37/Thr41. After MI, TGF-β1, and Wnt 1 levels are significantly increased, the overproduction of Wnt1 induces β-catenin stabilization and nuclear translocation through increasing the phosphorylation of disheveled (DVL) protein which in turn phosphorylates and inhibits GSK3β. TGF-β1 stimulates the phosphorylation of Smad-3 and subsequent nuclear translocation to activate the transcription of collage 1/III and α-smooth muscle actin (α-SMA). Besides, TGF-β1 stabilizes cytoplasmic β-catenin levels indirectly by phosphorylation of Akt at Thr308-induced inhibition of GSK3β by increasing phosphorylation of Ser9. Exendin-4, and possibly through G protein-coupled receptors (GPCRs), increases levels of cAMP and upregulates β-arrestin-2 levels. Both can result in a positive inotropic effect. Besides, β-arrestin-2 can stimulate PP2A to dephosphorylation Smad3 (inhibition) and GSK3β (activation), thus reduces fibrosis and prevents the activation of β-catenin and collagen deposition.
© 2020. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Exendin-4; GSK3β; Myocardial infarction; Remote ventricular remodeling; Wnt1; β-Catenin

Mesh:

Substances:

Year:  2021        PMID: 32474680     DOI: 10.1007/s10557-020-07006-9

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  65 in total

Review 1.  Infarct scar: a dynamic tissue.

Authors:  Y Sun; K T Weber
Journal:  Cardiovasc Res       Date:  2000-05       Impact factor: 10.787

Review 2.  Experimental myocardium infarction in rats: analysis of the model.

Authors:  Leonardo A M Zornoff; Sergio A R Paiva; Marcos F Minicucci; Joel Spadaro
Journal:  Arq Bras Cardiol       Date:  2009-10       Impact factor: 2.000

3.  Apoptosis in ischemic and reperfused rat myocardium.

Authors:  H Fliss; D Gattinger
Journal:  Circ Res       Date:  1996-11       Impact factor: 17.367

4.  Toll-like receptor-4 modulates survival by induction of left ventricular remodeling after myocardial infarction in mice.

Authors:  Alexander Riad; Sebastian Jäger; Meike Sobirey; Felicitas Escher; Aymaru Yaulema-Riss; Dirk Westermann; Aysun Karatas; Markus M Heimesaat; Stefan Bereswill; Duska Dragun; Matthias Pauschinger; Heinz P Schultheiss; Carsten Tschöpe
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

5.  DNA synthesis in the non-infarcted cardiac interstitium after left coronary artery ligation in the rat: effects of captopril.

Authors:  C van Krimpen; J F Smits; J P Cleutjens; J J Debets; R G Schoemaker; H A Struyker Boudier; F T Bosman; M J Daemen
Journal:  J Mol Cell Cardiol       Date:  1991-11       Impact factor: 5.000

6.  Interstitial collagen is increased in the non-infarcted human myocardium after myocardial infarction.

Authors:  P G Volders; I E Willems; J P Cleutjens; J W Arends; M G Havenith; M J Daemen
Journal:  J Mol Cell Cardiol       Date:  1993-11       Impact factor: 5.000

7.  Global cardiac remodeling after acute myocardial infarction: a study in the rat model.

Authors:  H F Weisman; D E Bush; J A Mannisi; B H Bulkley
Journal:  J Am Coll Cardiol       Date:  1985-06       Impact factor: 24.094

Review 8.  Myofibroblasts and inflammatory cells as players of cardiac fibrosis.

Authors:  Hitoshi Kurose; Supachoke Mangmool
Journal:  Arch Pharm Res       Date:  2016-08-11       Impact factor: 4.946

Review 9.  From Inflammation to Fibrosis-Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities.

Authors:  Navin Suthahar; Wouter C Meijers; Herman H W Silljé; Rudolf A de Boer
Journal:  Curr Heart Fail Rep       Date:  2017-08

10.  Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model.

Authors:  Paul Richards; Helen E Parker; Alice E Adriaenssens; Joshua M Hodgson; Simon C Cork; Stefan Trapp; Fiona M Gribble; Frank Reimann
Journal:  Diabetes       Date:  2013-12-02       Impact factor: 9.461

View more
  4 in total

1.  A novel soluble epoxide hydrolase vaccine protects murine cardiac muscle against myocardial infarction.

Authors:  Takahiro Kitsuka; Aya Shiraki; Jun-Ichi Oyama; Hironori Nakagami; Atsushi Tanaka; Koichi Node
Journal:  Sci Rep       Date:  2022-04-28       Impact factor: 4.996

Review 2.  GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential.

Authors:  Xiaoxuan Ma; Zhenghong Liu; Iqra Ilyas; Peter J Little; Danielle Kamato; Amirhossein Sahebka; Zhengfang Chen; Sihui Luo; Xueying Zheng; Jianping Weng; Suowen Xu
Journal:  Int J Biol Sci       Date:  2021-05-11       Impact factor: 6.580

Review 3.  Targeting myocardial ischaemic injury in the absence of reperfusion.

Authors:  M V Basalay; D M Yellon; S M Davidson
Journal:  Basic Res Cardiol       Date:  2020-10-14       Impact factor: 17.165

4.  Adipose-Derived Mesenchymal Stem Cells-Derived Exosomes Carry MicroRNA-671 to Alleviate Myocardial Infarction Through Inactivating the TGFBR2/Smad2 Axis.

Authors:  Xue Wang; Yuhai Zhu; Chengcheng Wu; Wennan Liu; Yujie He; Qing Yang
Journal:  Inflammation       Date:  2021-04-21       Impact factor: 4.092

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.